Skip to content

Skye Bioscience, Inc.: 10-Q filed 2020-08-13

What Skye Bioscience, Inc. reported in its quarterly report filed 2020-08-13 (fiscal Q2 2020): 33 published measures, 99 facts as tagged in accession 0001640334-20-002095.

This filing

Form
10-Q (quarterly report)
Filed
2020-08-13
Fiscal period
fiscal Q2 2020
Accession
0001640334-20-002095 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Skye Bioscience, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-06-30227,207USD
At 2019-12-311,996,743USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-06-303,321,631USD
At 2019-12-311,448,685USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-06-30-3,094,424USD
At 2020-03-31-1,702,897USD
At 2019-12-31548,058USD
At 2019-06-30-11,641,442USD
At 2019-03-31-27,864,191USD
At 2018-12-31-15,562,252USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-06-30102,524USD
At 2019-12-311,829,977USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-1,420,236USD91
2020-01-01 to 2020-06-30-3,761,896USD182
2020-01-01 to 2020-03-31-2,341,660USD91
2019-04-01 to 2019-06-3015,905,290USD91
2019-01-01 to 2019-06-301,130,898USD181
2019-01-01 to 2019-03-31-14,774,392USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-2,294,153USD182
2019-01-01 to 2019-06-30-3,036,246USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-06-30566,700USD182
2019-01-01 to 2019-06-303,990,699USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-06-30-35,935,178USD
At 2019-12-31-32,173,282USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-04-01 to 2020-06-30183,052,175shares91
2020-01-01 to 2020-06-30182,654,571shares182
2019-04-01 to 2019-06-30132,923,037shares91
2019-01-01 to 2019-06-30132,826,677shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-04-01 to 2020-06-30183,052,175shares91
2020-01-01 to 2020-06-30182,654,571shares182
2019-04-01 to 2019-06-30189,094,958shares91
2019-01-01 to 2019-06-30172,058,053shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-0.01USD/shares91
2020-01-01 to 2020-06-30-0.02USD/shares182
2019-04-01 to 2019-06-300.12USD/shares91
2019-01-01 to 2019-06-300.01USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-0.01USD/shares91
2020-01-01 to 2020-06-30-0.02USD/shares182
2019-04-01 to 2019-06-300.08USD/shares91
2019-01-01 to 2019-06-300.01USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-04-01 to 2020-06-301,600USD91
2020-01-01 to 2020-06-301,600USD182
2019-04-01 to 2019-06-301,600USD91
2019-01-01 to 2019-06-301,600USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-06-301,252USD
At 2019-12-311,983USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-04-01 to 2020-06-3028,709USD91
2020-01-01 to 2020-06-3092,851USD182
2019-04-01 to 2019-06-30173,084USD91
2019-01-01 to 2019-06-30344,577USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-1,220,658USD91
2020-01-01 to 2020-06-30-3,431,866USD182
2019-04-01 to 2019-06-30-1,770,887USD91
2019-01-01 to 2019-06-30-3,285,954USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-06-30225,955USD
At 2019-12-311,994,760USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-04-01 to 2020-06-30171,625USD91
2020-01-01 to 2020-06-30337,980USD182
2019-04-01 to 2019-06-30293,965USD91
2019-01-01 to 2019-06-30410,028USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-06-302,155,123USD
At 2019-12-31970,818USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-06-301,096,283USD
At 2019-12-31129,809USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-04-01 to 2020-06-301,220,658USD91
2020-01-01 to 2020-06-303,431,866USD182
2019-04-01 to 2019-06-301,770,887USD91
2019-01-01 to 2019-06-303,285,954USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-04-01 to 2020-06-30428,529USD91
2020-01-01 to 2020-06-301,228,141USD182
2019-04-01 to 2019-06-30688,041USD91
2019-01-01 to 2019-06-301,009,026USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-06-30183,207,747shares
At 2019-12-31182,895,247shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-06-30107,062USD
At 2019-12-311,834,515USD
At 2019-06-302,812,338USD
At 2018-12-311,857,885USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2020-06-3065,047USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-06-3037,726USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-1,418,636USD91
2020-01-01 to 2020-06-30-3,760,296USD182
2019-04-01 to 2019-06-3015,906,890USD91
2019-01-01 to 2019-06-301,132,498USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-04-01 to 2020-06-30792,129USD91
2020-01-01 to 2020-06-302,203,725USD182
2019-04-01 to 2019-06-301,082,846USD91
2019-01-01 to 2019-06-302,276,928USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-06-30731USD182
2019-01-01 to 2019-06-30731USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-197,978USD91
2020-01-01 to 2020-06-30-328,430USD182
2019-04-01 to 2019-06-3017,677,777USD91
2019-01-01 to 2019-06-304,418,452USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-01-01 to 2019-06-30165,277USD181

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2020-01-01 to 2020-06-301,600USD182
2019-01-01 to 2019-06-301,600USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-30966,474USD182
2019-01-01 to 2019-06-3057,862USD181

Inspect the source

Entity
Skye Bioscience, Inc. / CIK 0001516551
Captured
2026-09-20T09:13:51.237Z
SEC response SHA-256
fd229875bbe9efbf8ce715b00820b845a594b6e60bad8dd4ff739bde7e7cfc9e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001516551.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))